Best AI Index Fund to Buy
Over the last two years, companies with a focus on…
Buy
55
UHT Quote, Financials, Valuation and Earnings
Last price:
$39.93
Seasonality move
:
1.49%
Day range:
$39.37 - $39.94
52-week range:
$34.56 - $47.30
Dividend yield:
7.38%
P/E ratio:
29.41x
P/S ratio:
5.59x
P/B ratio:
3.19x
Volume:
65.1K
Avg. volume:
46.8K
1-year change:
5.84%
Market cap:
$550M
Revenue:
$99M
EPS (TTM):
$1.35
Analysts' Opinion
-
Consensus RatingUniversal Health Realty Income Trust has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $47.00, Universal Health Realty Income Trust has an estimated upside of 18.36% from its current price of $39.71.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $47.00 representing 100% downside risk from its current price of $39.71.
Fair Value
-
According to the consensus of 1 analyst, Universal Health Realty Income Trust has 18.36% upside to fair value with a price target of $47.00 per share.
UHT vs. S&P 500
-
Over the past 5 trading days, Universal Health Realty Income Trust has overperformed the S&P 500 by 2.82% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Universal Health Realty Income Trust does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Universal Health Realty Income Trust revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Universal Health Realty Income Trust reported revenues of $24.5M.
Earnings Growth
-
Universal Health Realty Income Trust earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Universal Health Realty Income Trust reported earnings per share of $0.34.
Enterprise value:
911.6M
EV / Invested capital:
1.69x
Price / LTM sales:
5.59x
EV / EBIT:
21.81x
EV / Revenue:
9.26x
PEG ratio (5yr expected):
1.91x
EV / Free cash flow:
19.49x
Price / Operating cash flow:
11.75x
Enterprise value / EBITDA:
13.16x
Gross Profit (TTM):
$92.9M
Return On Assets:
3.2%
Net Income Margin (TTM):
19.01%
Return On Equity:
10.16%
Return On Invested Capital:
3.4%
Operating Margin:
36.8%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $91.7M | $97.5M | $98.4M | $25.1M | $24.5M | |
| Gross Profit | $86.5M | $92.1M | $92.9M | $23.8M | $23.2M | |
| Operating Income | $31.1M | $33M | $36.4M | $9.5M | $9M | |
| EBITDA | $60.4M | $67.4M | $69.2M | $18.1M | $16.9M | |
| Diluted EPS | $1.46 | $1.17 | $1.35 | $0.38 | $0.34 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $17.2M | $104.8M | $106M | $123M | $120.3M | |
| Total Assets | $495.8M | $602.4M | $604.3M | $596.2M | $573.5M | |
| Current Liabilities | $259.4M | $287.2M | $319.1M | $344.9M | $360.1M | |
| Total Liabilities | $337.1M | $365.5M | $382.1M | $399.7M | $401.3M | |
| Total Equity | $158.7M | $237M | $222.2M | $196.5M | $172.2M | |
| Total Debt | $306.1M | $331.4M | $348.5M | $366.2M | $368.5M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $45.2M | $44.6M | $46.8M | $11.7M | $11.6M | |
| Cash From Investing | -$23.8M | -$22.6M | -$6.8M | -$8.9M | -$1.9M | |
| Cash From Financing | -$22.2M | -$22.4M | -$40.7M | -$3.3M | -$9.8M | |
| Free Cash Flow | $58.8M | $44.6M | $46.8M | $11.7M | $11.6M | |
UHT
Sector
Market Cap
$550M
$1.1B
Price % of 52-Week High
83.95%
82.85%
Dividend Yield
7.38%
3.24%
Shareholder Yield
6.86%
4.07%
1-Year Price Total Return
5.84%
--
Beta (5-Year)
0.921
0.756
Dividend yield:
7.38%
Annualized payout:
$2.92
Payout ratio:
216.69%
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$38.85
200-day SMA
Sell
Level
$40.55
Bollinger Bands (100)
Buy
Level
37.57 - 40.45
Chaikin Money Flow
Buy
Level
17.7M
20-day SMA
Buy
Level
$38.96
Relative Strength Index (RSI14)
Buy
Level
57.03
ADX Line
Buy
Level
10.46
Williams %R
Sell
Level
-9.8501
50-day SMA
Buy
Level
$39.01
MACD (12, 26)
Buy
Level
0.07
25-day Aroon Oscillator
Buy
Level
80
On Balance Volume
Sell
Level
-1.2M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.6961)
Sell
CA Score
(Annual)
Level (-0.8817)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (8)
Sell
Ohlson Score
Level (2.5297)
Buy
Piotroski F Score
(Annual)
Level (7)
Buy
Quality Ratio Score
Level (3)
Buy
Fundamental Score
Level (7)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Universal Health Realty Income Trust is a healthcare REIT. The company is engaged in the business of investing in and leasing healthcare and human service facilities through direct ownership or through joint ventures, which aggregate into a single reportable segment. The company actively manages a portfolio of healthcare and human service facilities. The revenue and net income are generated from the operation of the investment portfolio, located throughout the United States.
Stock Forecast FAQ
In the current month, UHT has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The UHT average analyst price target in the past 3 months is $47.00.
-
Where Will Universal Health Realty Income Trust Stock Be In 1 Year?
According to analysts, the consensus estimate is that Universal Health Realty Income Trust share price will rise to $47.00 per share over the next 12 months.
-
What Do Analysts Say About Universal Health Realty Income Trust?
Analysts are divided on their view about Universal Health Realty Income Trust share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Universal Health Realty Income Trust is a Sell and believe this share price will drop from its current level to $47.00.
-
What Is Universal Health Realty Income Trust's Price Target?
The price target for Universal Health Realty Income Trust over the next 1-year time period is forecast to be $47.00 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is UHT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Universal Health Realty Income Trust is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of UHT?
You can purchase shares of Universal Health Realty Income Trust via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Universal Health Realty Income Trust shares.
-
What Is The Universal Health Realty Income Trust Share Price Today?
Universal Health Realty Income Trust was last trading at $39.93 per share. This represents the most recent stock quote for Universal Health Realty Income Trust. Yesterday, Universal Health Realty Income Trust closed at $39.71 per share.
-
How To Buy Universal Health Realty Income Trust Stock Online?
In order to purchase Universal Health Realty Income Trust stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will Salesforce Stock Be in 5 Years?
Salesforce (NYSE: CRM) just turned in a quarter that, on…
2 Ultra Safe Dividend Stocks to Buy Now
Historically, blue-chip dividend stocks have been good choices for periods…
Stock Ideas
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 39x
Buy
65
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 46x
Buy
52
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Sell
31
REGN alert for Jun 2
Regeneron Pharmaceuticals [REGN] is up 0.8% over the past day.
Buy
55
RGC alert for Jun 2
Regencell Bioscience Holdings [RGC] is down 12.77% over the past day.
Sell
42
AMBA alert for Jun 2
Ambarella [AMBA] is down 0.55% over the past day.
